Clinical trial
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
NCT00104923 · California Cancer Consortium, Other · Completed
Key facts
| NCT number | NCT00104923 |
|---|---|
| Title | Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer |
| Official title | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | fenretinide |
| Enrollment | 29 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2017 |
| Completion | Apr 1, 2017 |
| First posted | Mar 4, 2005 |
| Last update posted | Jul 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: